Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca to Produce 2 Billion Doses of Its Coronavirus Vaccine Candidate

By Cory Renauer – Jun 4, 2020 at 4:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant signed agreements with heavy hitters in the vaccine manufacturing industry.

One of the programs championed by the White House's Warp Speed coronavirus vaccine project took another step forward Thursday. AstraZeneca (AZN -0.13%) signed new agreements on Thursday that will raise the global supply capacity for its experimental SARS-CoV-2 vaccine candidate to more than 2 billion doses.  

Making alliances

The experimental vaccine candidate that AstraZeneca licensed from Oxford University, ChAdOx1 nCoV-19, has a new name: AZD1222. It uses a non-replicating virus to carry genetic material for the SARS-CoV-2 spike protein, which should prime the immune system to attack the actual virus if encountered.

Person loading blood sample tubes.

Image source: Getty Images.

In May, AstraZeneca agreed to supply 400 million doses of AZD1222 to the U.S. and UK. On Thursday, the company reached a $750 million agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII) to supply 1 billion doses to low and middle-income countries. 

Testing under way

A phase 2/3 trial of AZD1222 with around 10,000 volunteers has already begun, and other late-stage studies with the vaccine candidate are expected to begin soon. Vaccine development can often be a frustrating endeavor, and there's a strong chance that AZD1222 won't be as effective as is hoped. Despite the risks, AstraZeneca is crossing its fingers and preparing to scale up manufacturing capacity without waiting for evidence the experimental vaccine works.

While demand for a SARS-CoV-2 vaccine is sky high, AstraZeneca has said it will provide access to AZD1222 to people around the world at no profit during the pandemic.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.